News

AstraZeneca and Daiichi Sankyo’s Enhertu has received conditional approval in China as a monotherapy for the treatment of adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received two or more prior...

Nanoform Finland Plc , the medicine performance-enhancing company announced that it is to enter into a pre-clinical development agreement with the Plasma-derived Therapies Business Unit of Takeda Pharmaceuticals, Inc., the R&D-driven biopharmaceutical company headquartered in Japan, to develop innovative...

Baxter International Inc., a global medtech leader, and funds managed by global investment firm Carlyle announced that they have signed a definitive agreement under which Carlyle is to acquire Baxter's Kidney Care segment, to be named Vantive, for $3.8...

Daiichi Sankyo and MSD have widened their partnership to create and market three DXd-based antibody-drug conjugates (ADCs) all over the world. DXd is the name of Daiichi Sankyo's unique ADC technology platform. MK-6070, MSD's delta-like ligand 3 (DLL3) targeting T-cell...

For an option on Biocytogen Pharmaceuticals' possible first-in-class B7H3/PTK7 BsADC program, Ideaya Biosciences is paying more than $400 million. The goal of antibody drug conjugates (ADCs) is to give highly focused therapy by combining the cytotoxic medicines with the...

The largest pharmaceutical company in the world based on market value, Eli Lilly, is getting into the nuclear isotope manufacturing industry as cancer medicine manufacturers want to ensure a supply of radioactive elements essential to the developing area of...

The life sciences industry is going through a big change right now, thanks to the fast growth of new treatments like cell and gene therapies (CAGT) and big new investments in radiopharmaceuticals. These new ideas have the ability to...